Stockscreener 앱 받기
3.17
2.59%
0.08
시간 외 거래:
3.27
0.10
+3.15%
전일 마감가:
$3.09
열려 있는:
$3.09
하루 거래량:
15,069
Relative Volume:
0.70
시가총액:
$7.26M
수익:
$2.98M
순이익/손실:
$-2.68M
주가수익비율:
-1.962
EPS:
-1.6157
순현금흐름:
$-2.29M
1주 성능:
+5.67%
1개월 성능:
+0.48%
6개월 성능:
+16.54%
1년 성능:
+2.26%
1일 변동 폭
$3.08
$3.27
1주일 범위
$2.93
$3.2932
52주 변동 폭
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
명칭
Xenetic Biosciences Inc
전화
781-778-7720
주소
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.17 | 7.08M | 2.98M | -2.68M | -2.29M | -1.6157 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-01-08 | 개시 | Maxim Group | Buy |
Xenetic Biosciences Inc 주식(XBIO)의 최신 뉴스
Xenetic’s Next Test: An ASCO Readout And The Cash Question - Finimize
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Times Herald
Xenetic Biosciences Grants Equity Award to Interim CEO - The Globe and Mail
Xenetic Biosciences, Inc. Files Form 8-K Announcing Restricted Stock Award Agreement for CEO James Parslow - Minichart
Xenetic Biosciences, Inc. 2025 Annual Report 10-K/A: Executive Compensation, Governance, and Shareholder Information - Minichart
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting - Times Argus
Xenetic Biosciences (NASDAQ: XBIO) updates CEO pay, ownership in 10-K/A - Stock Titan
Xenetic Biosciences (NASDAQ: XBIO) grants CEO/CFO 100,000 restricted shares - Stock Titan
Xenetic Biosciences (XBIO) interim CEO awarded 100,000-share restricted stock grant - Stock Titan
Cancer drug research from Xenetic gets June poster slot at ASCO - Stock Titan
Xenetic Biosciences (XBIO) Stock: Pricing Analysis (Momentum Fading) 2026-04-20Resistance Breakout - Xã Vĩnh Công
Xenetic Biosciences Inc (XBIOW) - Minichart
Xenetic Biosciences (XBIO) Stock Rallies on Launch (Bullish Sentiment) 2026-04-15Real-time Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Investment Report: Can Xenetic Biosciences Inc maintain sales growth2026 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Published on: 2026-04-13 21:59:57 - baoquankhu1.vn
XBIO Q2 2025 Earnings: Xenetic Biosciences Inc. beats EPS views, reports zero revenue - UBND thành phố Hải Phòng
History Review: Is Xenetic Biosciences Inc stock good for income investors2026 Patterns & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Sectors Review: Is Xenetic Biosciences Inc stock undervalued right nowTrade Risk Summary & Verified Momentum Watchlists - baoquankhu1.vn
Loss Report: Is Xenetic Biosciences Inc a potential multi baggerWeekly Risk Report & Risk Controlled Stock Alerts - baoquankhu1.vn
XBIO PE Ratio & Valuation, Is XBIO Overvalued - Intellectia AI
XBIO.WS (Xenetic Biosciences) PB Ratio : (As of Apr. 04, 2026) - gurufocus.com
XBIO Q4 Earnings: Beats Estimates by $0.20 - Cổng thông tin điện tử tỉnh Tây Ninh
Highs Report: Is now the right time to enter Xenetic Biosciences Inc2026 PreEarnings & Weekly High Conviction Ideas - baoquankhu1.vn
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update - Defense World
Published on: 2026-03-27 18:33:00 - baoquankhu1.vn
Aug Volume: Is Xenetic Biosciences Inc on track to beat earningsQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Analyst Calls: Can Xenetic Biosciences Inc be recession proof2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Xenetic (XBIO) Reports Increased Revenue and Advances Clinical D - GuruFocus
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results - Bitget
[8-K] Xenetic Biosciences, Inc. Reports Material Event | XBIO SEC FilingForm 8-K - Stock Titan
Cancer biotech Xenetic grows Takeda royalties to $3M, trims costs - Stock Titan
Xenetic Biosciences: Fourth Quarter Financial Results Overview - Bitget
Xenetic Biosciences 2025 Annual Report: Advancing DNase Immuno-Oncology Technology for Solid Tumors and Strategic Business Developments - Minichart
Xenetic Biosciences: Q4 Earnings Snapshot - KTVB
XBIO: Revenue up 19%, net loss narrows, DNase oncology focus, strategic review underway - TradingView
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
XBIO SEC FilingsXenetic Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Risk On: Can Xenetic Biosciences Inc be recession proofWeekly Profit Summary & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Big Money Moves: Is Xenetic Biosciences Inc stock a value trapJuly 2025 Retail & Community Consensus Stock Picks - baoquankhu1.vn
Published on: 2026-03-07 03:26:22 - baoquankhu1.vn
Xenetic Biosciences adjourns 2025 annual meeting - MSN
Can Xenetic Biosciences Inc be recession proofTrade Performance Summary & Fast Gain Stock Tips - baoquankhu1.vn
XBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analyst Downgrade: Can Xenetic Biosciences Inc be recession proofQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
XBIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results - Montgomery Advertiser
XBIO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Xenetic Biosciences Inc. (XBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
XBIO Should I Buy - Intellectia AI
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest - Defense World
Trading Recap: Is AMKR stock a value trapWeekly Loss Report & Growth Focused Stock Reports - baoquankhu1.vn
Xenetic Biosciences Inc (XBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):